Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
November 2021—DiaSorin Molecular announced that it has CE marked its Simplexa COVID-19 and Flu A/B Direct kit. The multiplex test allows for the in vitro qualitative detection and differentiation of nucleic acid from SARS-CoV-2, influenza A, and influenza B from a patient sample in one reaction well. The assay is designed for use on the Liaison MDX and is run directly from nasopharyngeal swabs without the need for off-board extraction.
November 2021—Microbiologics has launched its SARS-CoV-2 Whole Virus Antigen Control, which can be used in the point-of-care setting for the detection of SARS-CoV-2 antigens and for monitoring the extraction, amplification, and detection in nucleic acid testing. In antigen-based applications, the high titer formula provides a clear positive reaction to monitor the detection of SARS-CoV-2 viral antigens. Each kit contains six individually packaged lyophilized swabs.
November 2021—Roche launched in the CE market three molecular PCR diagnostic test panels to simultaneously detect and differentiate flu A, flu B, and respiratory syncytial virus; adenovirus, human metapneumovirus, and enterovirus/rhinovirus; and parainfluenza 1, 2, 3, and 4. The tests can be run together or individually from a single nasopharyngeal swab specimen and run on the Cobas Omni Utility Channel for use with the Cobas 6800/8800 systems.
October 2021—BD launched the BD FACSymphony A1 Cell Analyzer, a fluorescence-activated cell analyzer that offers advanced research capabilities in a benchtop design. Fluorescence-activated cell sorter (FACS) technology enables precise isolation of selected single cells from complex samples.
October 2021—Siemens Healthineers has launched Sysmex’s CN-3000 and CN-6000 hemostasis systems for mid- and high-volume coagulation testing. A broad menu of Siemens’ routine and specialty coagulation assays that help identify blood coagulation disorders such as abnormal blood clotting or bleeding, including Siemens’ Innovance Anti-Xa assay for heparin and direct oral anticoagulant testing, can be performed on the CN-3000 and CN-6000 instruments.
October 2021—Bio-Rad Laboratories has launched SARS-CoV-2 S gene alpha, beta, gamma, and epsilon variant controls.
October 2021—Mesa Laboratories has entered into a definitive agreement to acquire Agena Bioscience for a cash price of $300 million, subject to customary purchase price adjustments. The transaction is expected to be completed by Dec. 31 and is subject to customary conditions, including receipt of applicable regulatory approvals.
October 2021—Cepheid received FDA emergency use authorization for its Xpert Xpress CoV-2/Flu/RSV Plus, a rapid molecular diagnostic test for qualitative detection of the viruses causing COVID-19, flu A, flu B, and respiratory syncytial virus infections from a single patient sample. The Plus version of the test provides three gene targets for SARS-CoV-2 detection—N2, E, and RdRP. The test is designed for use on any GeneXpert system and results are delivered in about 36 minutes.
October 2021—Thermo Fisher Scientific announced a suite of Ion Torrent Oncomine immune repertoire assays designed to detect potentially malignant clones of T cells and B cells. Using proprietary Ion AmpliSeq technology, the pan-clonality assays target multiple parts of the B- and T-cell immune receptors using a single reaction with ultra-high sensitivity.
October 2021—Thermo Fisher Scientific announced FDA emergency use authorization of the TaqPath COVID-19 Fast PCR Combo Kit 2.0 and TaqPath COVID-19 RNase P Combo Kit 2.0. Both kits are updated versions of tests, with increased genomic target redundancy to ensure continued accuracy as SARS-CoV-2 mutates.
